Smallpox Vaccines for Biodefense: Need and Feasibility

Andrew W Artenstein; John D Grabenstein


Expert Rev Vaccines. 2008;7(8):1225-1237. 

In This Article

Five-year View

Current stockpiles of first- and second-generation smallpox vaccines serve as an important contingency position for emergent circumstances. Newer-generation smallpox vaccines that employ highly attenuated and/or nonreplicative forms of vaccinia or sub-unit vaccine approaches, some with promising preclinical data, may provide significantly safer, effective alternatives over the next 5 years that will enhance biodefense strategies. Viral subunit strategies, in particular, may provide a flexible platform in the future upon which to build capabilities for protection against genetically altered forms of smallpox.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.